Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT  
74.99
+14.36 (+23.68%)
Products, Regulatory

Arcturus Therapeutics Announces Positive Interim Arct-021 Phase 1/2 Study Results For Both Single Shot And Prime-Boost Regimens

Published: 11/09/2020 12:23 GMT
Arcturus Therapeutics Ltd (ARCT) - Arcturus Therapeutics Announces Positive Interim Arct-021 (lunar-cov19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens.
Arcturus Therapeutics Holdings Inc - Up to $220 Million in Additional Financial Commitments From Singapore.
Arcturus Therapeutics Holdings Inc - Lyophilized Drug Product on Track for Phase 3 Implementation.
Arcturus - Based on Results, Single 7.5 Μg Dose of Arct-021, With Prime-boost Regimens Are Selected to Advance Into Later Stage Global Clinical Trials.
Arcturus Therapeutics Holdings Inc - Based on Interim Study Results, Robust Anti-spike Protein Igg Immune Response Was Observed at All Doses Evaluated.
Arcturus Therapeutics Holdings Inc - Arct-021 Was Generally Well Tolerated and Had a Favorable Local and Systemic Adverse Event (ae) Profile.
Arcturus - Agreement With Singapore's Edb Includes a Limited Recourse Loan of $45 Million & Terms for Arct-021 Vaccine Purchases of Up to $175 Million.